ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced long-term results of the Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). With the trial fully enrolled and all patients evaluable, 72% of chronic-phase CML patients treated with ponatinib achieved a major cytogenetic response (MCyR), including 92% of patients who also had a T315I mutation. Since the last data update from the trial was presented in December, 2010, all chronic-phase CML patients who achieved a MCyR remain in response with no signs of resistance.
Read the full article and disclaimer at: http://pennyomega.com/?p=17483
(ARIA, ANGO, QLGC, CRWE) Stock Highlights by PennyOmega.com
September 30th, 2011 at 12:57 pm